- Home
- LVLU vs SNY Comparison
LVLU vs SNY Comparison
Compare LVLU & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LVLU
- SNY
- Stock Information
- Founded
- LVLU 1996
- SNY 1994
- Country
- LVLU United States
- SNY France
- Employees
- LVLU N/A
- SNY N/A
- Industry
- LVLU Catalog/Specialty Distribution
- SNY Biotechnology: Pharmaceutical Preparations
- Sector
- LVLU Consumer Discretionary
- SNY Health Care
- Exchange
- LVLU Nasdaq
- SNY Nasdaq
- Market Cap
- LVLU N/A
- SNY 123.6B
- IPO Year
- LVLU 2021
- SNY N/A
- Fundamental
- Price
- LVLU $0.41
- SNY $50.33
- Analyst Decision
- LVLU Hold
- SNY Buy
- Analyst Count
- LVLU 2
- SNY 2
- Target Price
- LVLU $1.00
- SNY $62.50
- AVG Volume (30 Days)
- LVLU 146.8K
- SNY 3.1M
- Earning Date
- LVLU 05-14-2025
- SNY 04-24-2025
- Dividend Yield
- LVLU N/A
- SNY 3.09%
- EPS Growth
- LVLU N/A
- SNY 39.56
- EPS
- LVLU N/A
- SNY 5.45
- Revenue
- LVLU $315,887,000.00
- SNY $48,817,552,946.00
- Revenue This Year
- LVLU N/A
- SNY $5.35
- Revenue Next Year
- LVLU $2.76
- SNY $6.69
- P/E Ratio
- LVLU N/A
- SNY $9.56
- Revenue Growth
- LVLU N/A
- SNY N/A
- 52 Week Low
- LVLU $0.33
- SNY $45.80
- 52 Week High
- LVLU $1.99
- SNY $60.12
- Technical
- Relative Strength Index (RSI)
- LVLU 43.07
- SNY 39.23
- Support Level
- LVLU $0.40
- SNY $51.67
- Resistance Level
- LVLU $0.44
- SNY $55.73
- Average True Range (ATR)
- LVLU 0.04
- SNY 0.88
- MACD
- LVLU 0.00
- SNY -0.09
- Stochastic Oscillator
- LVLU 36.90
- SNY 7.84
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.